Connect with us

Health

New antibody suppresses HIV for 28 days

Researchers hopeful findings can lead to yearly dosage

Published

on

vaccine, meningitis, gay news, Washington Blade
antibody, funding LGBT health, medical, shot, gay news, Washington Blade, gay news

Researchers say their goal is a once-a-year shot for HIV prevention.

LONDON — A new lab-made antibody can suppress HIV for up to 28 days after only a single dose, researchers at the Rockefeller University in New York have found, according to a Gay Star News article.

Their work was published in the journal Nature on April 8 and was the first time that a new generation of HIV antibodies had been tested in humans, the article said.

“We conclude that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV-1 prevention, therapy and cure,” wrote the study’s lead author, Michel Nussenzweig.

“The goal is a once-a-year shot for prevention and a combination approach for cure,” he added, much like cancer treatment.

The 3BN117 antibody shows activity against 195 out of 237 HIV strains and earlier work demonstrated that it can prevent or suppress infection in mouse and non-human primate models of HIV, Gay Star News reports.

In the new study, 17 HIV-infected and 12 uninfected individuals were injected with a single dose of the antibody and monitored for 56 days. At the highest dosage level, 30 milligrams per kilogram of weight, all eight infected individuals treated showed up to 300-fold decreases in the amount of virus measured in their blood, researchers found according to the Gay Star News article.

HIV antibodies previously tested in humans had disappointing results but 3BNC117 belongs to a new generation of broadly neutralizing antibodies.

“What’s special about these antibodies is that they have activity against over 80 percent of HIV strains and they are extremely potent,” said Marina Caskey, assistant professor of clinical investigation in the Nussenzweig lab and co-first author of the study.

Broadly neutralizing antibodies are produced naturally in some 10-30 percent of people with HIV, but only after several years of infection. By that time the virus has usually developed a resistance, Gay Star News reports.

But by isolating and cloning these antibodies, researchers were able to harness them as therapeutic agents against HIV infections that have had less time to prepare.

“In contrast to conventional antiretroviral therapy, antibody-mediated therapy can also engage the patient’s immune cells, which can help to better neutralize the virus,” said co-first author Florian Klein, also assistant professor of clinical investigation in the Nussenzweig laboratory, according to the article.

Nussenzweig’s group has produced a second HIV antibody and hopes to test it alone and in combination with 3BNC117 this year, the report said.

Advertisement
FUND LGBTQ JOURNALISM
SIGN UP FOR E-BLAST

Health

MISTR announces it’s now prescribing DoxyPE

Published

on

MISTR, the telemedicine provider that offers free online PrEP and long-term HIV care in all 50 states, D.C., and Puerto Rico, announced it is now prescribing Doxycycline Post-Exposure Prophylaxis (DoxyPEP), an antibiotic that reduces bacterial STIs, including gonorrhea, chlamydia, and syphilis. Patients can now use MISTR’s telehealth platform to receive DoxyPEP online for free, according to a release from the company.

With this launch, MISTR plans to offer patients access to post-exposure care, in addition to its existing preventive and long-term HIV treatment options, which include PrEP and antiretroviral therapy (ART). This comes at a time when the rate of STIs continue to rise. In 2022, more than 2.5 million cases of syphilis, gonorrhea, and chlamydia were reported in the U.S; of that population, gay and bisexual men are disproportionately affected, the company reported.

“Despite an ongoing STI epidemic affecting the LGBTQ+ community, there are few resources available for this underserved, vulnerable community to get the preventative medication they need,” said Tristan Schukraft, CEO and founder of MISTR. “I’m proud that MISTR is democratizing access to PrEP, HIV care, and now DoxyPEP.”

An NIH-funded study published by the New England Journal of Medicine in April 2023 found that doxycycline as post-exposure prophylaxis, now known as DoxyPEP, reduced syphilis by 87%, chlamydia by 88%, and gonorrhea by 55% in individuals taking HIV PrEP, and reduced syphilis by 77%, chlamydia by 74% and gonorrhea by 57% in people living with HIV. 

MISTR is a telemedicine platform offering free online access to pre-exposure prophylaxis (PrEP) and long-term HIV care Visit mistr.com for more information.

Continue Reading

Health

UNAIDS to commemorate Zero Discrimination Day’s 10th anniversary

UN agency urges global action to protect human rights

Published

on

A UNAIDS anti-discrimination exhibit at Tocumen International Airport in Panama in 2018. (Washington Blade photo by Michael K. Lavers)

As the world marks the 10th anniversary of Zero Discrimination Day; UNAIDS is sounding the alarm on the increasing threats to human rights, calling for renewed efforts to protect the rights of all individuals as a fundamental step towards ensuring health for everyone.

Established by UNAIDS a decade ago, Zero Discrimination Day aims to promote equality and fairness regardless of gender, age, sexuality, ethnicity or HIV status. The progress achieved over the past years is now in jeopardy, however, due to rising attacks on the rights of women, LGBTQ people and other marginalized communities.

UNAIDS Executive Director Winnie Byanyima emphasized the critical link between protecting human rights and safeguarding public health. 

“The attacks on rights are a threat to freedom and democracy and are harmful to health,” she said in a press release. “Stigma and discrimination obstruct HIV prevention, testing, treatment and care and hold back progress towards ending AIDS by 2030. It is only by protecting everyone’s rights that we can protect everyone’s health.”

Despite challenges, there has been notable progress. 

At the onset of the AIDS pandemic more than 40 years ago, two-thirds of countries criminalized consensual same-sex sexual relations. They are now decriminalized in two-thirds of countries. An additional 38 countries around the world have pledged to end HIV-related stigma and discrimination, contributing to positive changes that include 50 million more girls attending school compared to 2015.

To sustain and enhance these advancements; UNAIDS urges global support for women’s rights movements, LGBTQ rights, racial justice, economic justice, climate justice and peace initiatives. By standing with communities advocating for their rights, the U.N. aims to reinforce the collective effort towards a more inclusive and equitable world.

Zero Discrimination Day is observed on March 1.

Events and activities that will take place around the world throughout the month will serve as reminders of the essential lesson and call to action: Protecting everyone’s health is synonymous with protecting everyone’s rights.

“Through upholding rights for all, we will be able to achieve the Sustainable Development Goals and secure a safer, fairer, kinder and happier world — for everyone,” said Byanyima.

Continue Reading

Health

New CDC report finds transgender women at higher risk for HIV

More than 1,600 people in seven cities surveyed

Published

on

The Centers for Disease Control and Prevention in Atlanta (Photo courtesy of the CDC)

The Centers for Disease Control and Prevention issued a new study report this week that revealed that restricted by employment and housing discrimination and lack of access to needed gender-affirming healthcare for transgender women increasing the risk of contracting HIV. 

Researchers reviewed data from a 2019-2020 survey, the National HIV Behavioral Surveillance Among Transgender Women, which found that the demographics of HIV/AIDS have been disproportionally high, especially among Black and Latina trans women, who had experienced employment and housing discrimination coupled with lack of access to gender-affirming healthcare.

The Jan. 25 Morbidity and Mortality Weekly Report was based on data studies of more than 1,600 trans women in seven major urban locales. Participants from Atlanta, Los Angeles, New Orleans, New York, Philadelphia, San Francisco and Seattle were chosen by referrals from people and community-based organizations who knew or were part of the local population of trans women.

The study’s researchers noted: “Employment discrimination occurs at the overlapping nexus of poverty, homelessness, incarceration, health insurance, disability, food insecurity and survival sex work. These issues are interconnected.”

The study stated that trans women’s inability to access quality healthcare, including gender-affirming treatment or access to PrEP, and can expose them to potential incarceration as many turn to “survival sex work” and violence, which increases the risk of contracting HIV. 

The study’s author’s pointed out: “When economically marginalized transgender women are refused employment, this refusal cyclically contributes to economic hardships. This analysis …demonstrates the importance of transgender women working and living with dignity and without fear of unfair treatment.”

Continue Reading
Advertisement
Advertisement

Sign Up for Weekly E-Blast

Follow Us @washblade

Advertisement

Popular